

1. Identification

Product identifier	Doxazosin Mesylate		
Other means of identification			
Catalog number	1225419		
Chemical name	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-, monomethanesulfonate		
Synonym(s)	Doxazosin methanesulfonate		
Recommended use	Specified quality tests and assay use only.		
Recommended restrictions	Not for use as a drug. Not for administration to humans or animals.		
Manufacturer/Importer/Supplier/Distributor information			
Company name	U. S. Pharmacopeia		
Address	12601 Twinbrook Parkway Rockville MD 20852-1790 US		
Telephone	RS Technical Services	301-816-8129	
Website	www.usp.org		
E-mail	RSTECH@usp.org		
Emergency phone number	CHEMTREC within US & Canada	1-800-424-9300	
	CHEMTREC outside US & Canada	+1 703-527-3887	

2. Hazard(s) identification

Note	This product is supplied in a small quantity which does not constitute a combustible dust hazard. The physical properties of this material indicate that in large quantities accumulated dust may be hazardous.		
Physical hazards	Not classified.		
Health hazards	Specific target organ toxicity, single exposure	Category 1 (cardiovascular system)	
OSHA hazard(s)	Not classified.		
Label elements			



Signal word	Danger		
Hazard statement	Causes damage to organs (cardiovascular system).		
Precautionary statement			
Prevention	Wash thoroughly after handling.		
Response	If exposed: Call a poison center/doctor.		
Storage	Store locked up.		
Disposal	Dispose of contents/container in accordance with local/regional/national/international regulations.		
Hazard(s) not otherwise classified (HNOC)	Not classified.		

3. Composition/information on ingredients

Substance

Hazardous components

Chemical name	Common name and synonyms	CAS number	%
Doxazosin Mesylate	Doxazosin methanesulfonate	77883-43-3	100

4. First-aid measures

Inhalation	Move to fresh air. Call a physician if symptoms develop or persist.
Skin contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately.
Most important symptoms/effects, acute and delayed	Cardiovascular effects.
Indication of immediate medical attention and special treatment needed	Treatment of alpha-adrenergic blocker overdose should be symptomatic and supportive and may include the following: Induced vomiting is NOT recommended. Administer activated charcoal as a slurry. Perform gastric lavage soon after ingestion (within one hour). Protect airway by placement in Trendelenburg and left lateral decubitus position or by endotracheal intubation. Control any seizures first. For seizures, administer intravenous diazepam or lorazepam. If seizures recur, consider phenobarbital. Monitor for hypotension, dysrhythmias, respiratory depression, and need for endotracheal intubation. Evaluate for hypoglycemia, electrolyte disturbances, and hypoxia. For circulatory failure, treat by placing patient in supine position and elevating legs. For shock, treat as necessary. Volume expanders may be used, followed by cautious administration of an intravenous vasopressor if needed. For hypotension, infuse isotonic fluid. If hypotension persists, administer norepinephrine. Epinephrine should not be used due to the risk of further hypotension. Priapism is a surgical emergency. Dialysis is unlikely to be of benefit. Monitor fluid and electrolyte status. [Meditext]
General information	Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention.

5. Fire-fighting measures

Suitable extinguishing media	Use fire-extinguishing media appropriate for surrounding materials. Water. Foam. Dry chemical or CO ₂ .
Unsuitable extinguishing media	None known.
Specific hazards arising from the chemical	Explosion hazard: Avoid generating dust; fine dust dispersed in air in sufficient concentrations and in the presence of an ignition source is a potential dust explosion hazard.
Special protective equipment and precautions for firefighters	Wear suitable protective equipment.
Fire-fighting equipment/instructions	Use water spray to cool unopened containers. As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Avoid inhalation of dust from the spilled material. Wear appropriate personal protective equipment.
Methods and materials for containment and cleaning up	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Clean surface thoroughly to remove residual contamination.

7. Handling and storage

Precautions for safe handling	Combustible dust clouds may be created where operations produce fine material (dust). Avoid significant deposits of material, especially on horizontal surfaces, which may become airborne and form combustible dust clouds and may contribute to secondary explosions. As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly. Use of a designated area is recommended for handling of potent materials.
Conditions for safe storage, including any incompatibilities	Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

8. Exposure controls/personal protection

Exposure limit values

Industrial Use

Material	Type	Value
Doxazosin Mesylate (CAS 77883-43-3)	TWA	30 micrograms/m3

Biological limit values

No biological exposure limits noted for the ingredient(s).

Appropriate engineering controls

Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials. Local exhaust ventilation such as a laboratory fume hood or other vented enclosure is recommended, particularly for grinding, crushing, weighing, or other dust-generating procedures.

Individual protection measures, such as personal protective equipment

Eye/face protection

Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.

Skin protection

Hand protection

Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.

Other

For handling of laboratory scale quantities, a cloth lab coat is recommended. Where significant quantities are handled, work clothing may be necessary to prevent take-home contamination.

Respiratory protection

Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134).

Thermal hazards

Not available.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

9. Physical and chemical properties

Appearance

White to tan colored powder.

Physical state

Solid.

Form

Powder.

Odor

Essentially odorless.

Odor threshold

Not available.

pH

Not available.

Melting point/freezing point

523.4 - 530.6 °F (273 - 277 °C)

Initial boiling point and boiling range

Not available.

Flash point

Not available.

Evaporation rate

Not available.

Flammability (solid, gas)

Not applicable.

Upper/lower flammability or explosive limits

Flammability limit - lower (%)

Not available.

Flammability limit - upper (%)

Not available.

Explosive limit - lower (%)

Not available.

Explosive limit - upper (%)

Not available.

Vapor pressure

< 0.0000001 kPa at 25 °C

Vapor density

Not available.

Relative density

Not available.

Solubility in water

Very slightly soluble.

Partition coefficient (n-octanol/water)

Not available.

Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Chemical family	Piperazinyll quinazoline.
Dust explosion properties	
Minimum explosible concentration (MEC)	2 g/cu. ft
Molecular formula	C23-H25-N5-O5.C-H4-O3-S
Molecular weight	547.59 g/mol
Potential for dust explosion	Severe dust deflagration hazard. Sensitive to ignition by electrostatic discharge.
Solubility (other)	Freely soluble in formic acid and dimethylsulfoxide; soluble in dimethylformamide; slightly soluble in ethanol; very slightly soluble in methanol, in acetone, and in methylene chloride.

10. Stability and reactivity

Reactivity	No reactivity hazards known.
Chemical stability	Stable at normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	None known.
Incompatible materials	Strong oxidizers.
Hazardous decomposition products	NOx, SOx. Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions.

11. Toxicological information

Information on likely routes of exposure

Ingestion	Based on available data, the classification criteria are not met.
Inhalation	Due to lack of data the classification is not possible.
Skin contact	Due to lack of data the classification is not possible.
Eye contact	Due to lack of data the classification is not possible.

Symptoms related to the physical, chemical, and toxicological characteristics Alpha-adrenergic blockers: Nausea. Vomiting. Headache. Dizziness. Lightheadedness. Fainting. Drowsiness. Sleepiness. Nervousness. Restlessness. Irritability. Tiredness. Weakness. Shortness of breath. Swelling of feet or lower legs. Chest pain. Back pain. Joint pain. Blurred vision. Fast, pounding, or irregular heartbeat. Abnormal ejaculation. Decreased sexual desire.

Delayed and immediate effects of exposure Alpha-adrenergic blockers: Upper respiratory tract infection. Low blood pressure.

Cross sensitivity Persons sensitive to one quinazoline may be sensitive to this material also.

Medical conditions aggravated by exposure Alpha-adrenergic blockers: Active alcoholism. Heart disease. Impaired liver function.

Acute toxicity Based on available data, the classification criteria are not met.

Product	Species	Test Results
Doxazosin Mesylate (CAS 77883-43-3)		
<i>Oral</i>		
LD50	Rat	> 5000 mg/kg
Skin corrosion/irritation	Due to lack of data the classification is not possible.	
Serious eye damage/eye irritation	Due to lack of data the classification is not possible.	
Respiratory sensitization	Due to lack of data the classification is not possible.	
Skin sensitization	Due to lack of data the classification is not possible.	
Germ cell mutagenicity	Due to lack of data the classification is not possible. Data from germ cell mutagenicity tests were not found.	

Mutagenicity

Ames test in *S. typhimurium*
Result: Negative.
Forward mutation assay in *E. coli*
Result: Negative.
In vitro cytogenetics assay in human lymphocytes
Result: Negative.

Mutagenicity

In vivo cytogenetics assay in mouse bone marrow
Result: Negative.

Carcinogenicity

Based on available data, the classification criteria are not met.
This material is not considered to be a carcinogen by IARC, NTP, or OSHA.

0 - 120 mg/kg/day Carcinogenicity study in mice

Result: No evidence of carcinogenic potential.

Test Duration: 24 months

0 - 40 mg/kg/day Carcinogenicity study in rats

Result: No evidence of carcinogenic potential.

Test Duration: 24 months

Reproductive toxicity

Based on available data, the classification criteria are not met.

Reproductivity

0 - 20 mg/kg/day Reproductivity study in rats

Result: No evidence of teratogenicity, but fertility was reduced in males.

0 - 41 mg/kg/day Reproductivity study in pregnant rabbits

Result: No evidence of teratogenicity; however, doses of 82 mg/kg reduced fetal survival.

Specific target organ toxicity - single exposure

Causes damage to organs (cardiovascular system).

Specific target organ toxicity - repeated exposure

Due to lack of data the classification is not possible.

Aspiration hazard

Based on available data, the classification criteria are not met.

12. Ecological information**Ecotoxicity****Product****Species****Test Results**

Doxazosin Mesylate (CAS 77883-43-3)

Acute

Crustacea

LC50

Daphnia magna

> 5 mg/l, 48 hours

Persistence and degradability

No data is available on the degradability of this product.

Bioaccumulative potential

Not available.

Mobility in soil

Not available.

Other adverse effects

Not available.

13. Disposal considerations**Disposal instructions**

Dispose in accordance with all applicable regulations.

Local disposal regulations

Not available.

Hazardous waste code

Not available.

Waste from residues / unused products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging

Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information**DOT**

Not regulated as a hazardous material by DOT.

IATA

Not regulated as a dangerous good.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

No information available.

15. Regulatory information**US federal regulations**

CERCLA/SARA Hazardous Substances - Not applicable.

One or more components are not listed on TSCA.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories
Immediate Hazard - No
Delayed Hazard - No
Fire Hazard - Yes
Pressure Hazard - No
Reactivity Hazard - No

SARA 302 Extremely hazardous substance No

SARA 311/312 Hazardous chemical No

Other federal regulations

Safe Drinking Water Act (SDWA) Not regulated.

Food and Drug Administration (FDA) Not regulated.

US state regulations

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	Yes
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	Yes
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

16. Other information, including date of preparation or last revision

Issue date 02-07-2011

Revision date 08-08-2014

Version # 02

Further information Refer to NFPA 654, Standard for the Prevention of Fire and Dust Explosions from the Manufacturing, Processing, and Handling of Combustible Particulate Solids, for safe handling.

Disclaimer USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.

Revision Information This document has undergone significant changes and should be reviewed in its entirety.